Abstract Introduction The assessment of the risks and benefits of genetic/genomic tests has long been addressed using various frameworks. They are mostly ACCE-based, focus on technical aspects, but often overlook economic and organizational considerations. The few HTA-based approaches, though more comprehensive, lack validation and implementation. This review’s purpose is to identify all evaluation frameworks for genetic/genomic tests and synthesize their key aspects. Methods PubMed, Scopus, Web of Science, and Google Scholar were searched. Inclusion criteria were documents describing evaluation frameworks for genetic/genomic tests, that were original, specifically created, and covering at least three assessment domains. This study was supported by the EC and MUR under PNRR - M4C2-I1.3 Project PE_00000019 ‘HEAL ITALIA’. Results Overall, 12546 unique records were screened, of which 67 documents were assessed for eligibility. A total of 29 studies were included, reporting 24 different frameworks. These frameworks were published between 2000 and 2019, mostly from USA (50%), Canada (13%) and UK (13%). There was substantial interest in the economic facets of the technology (92%), albeit without extensive detail, and high attention was given to its technical accuracy (70-90%). The clinical value was also consistently mentioned (70-90%), similarly to legal, ethical, and social considerations (70-80%). However, there was minimal emphasis on non-health outcomes (20-50%), and insufficient attention to organizational, educational, and implementation barriers (20-50%). Discussion A pressing need exists for a universally accepted evaluation framework for genetic/genomic tests. Applying a general HTA methodology, potentially based on the EUnetHTA core model, that can integrate solid theoretical and methodological principles, and result in a validated, comprehensive, and widely shared tool for genetic test evaluation, is a viable option to foster the implementation of these technologies. Key messages • Genetic/genomic test evaluations focus on technical accuracy and clinical value, often missing economic and organizational aspects. • A universal, validated, HTA-based evaluation framework for genetic/genomic tests is needed to enhance their implementation in clinical practice.